Albumin May Predict Prognosis in Guillain-Barré Syndrome
A simple measurement of serum albumin concentration could represent a prognostic biomarker in patients with Guillain-Barré syndrome (GBS) treated with intravenous immunoglobulin (IVIG), a new study suggests.

The study showed that 35% of patients with GBS developed hypoalbuminemia (serum albumin <3.5 g/dL) 2 weeks after IVIG treatment and that low albumin levels after treatment were strongly related to a severe clinical course and poor outcome...